EPCAM and colon carcinoma: Thus, Mashreghi et al. [135] proposed surface-functionalized PEGylated-nanoliposomal DOXorubicin, with an anti-EpCAM (epithelial cell adhesion molecule) aptamer to active targeting colon carcinoma C26 cells.